BioCentury | Oct 21, 2020
Product Development

UCSF’s virus-host protein interaction maps ID targets for COVID-19, future coronaviruses

A UCSF-led team has identified host pathways that could inform development of countermeasures against future coronaviruses, as they interact with multiple coronaviruses that recently made the leap...
BioCentury | Feb 15, 2019
Company News

India's Glenmark spinning out innovative assets into U.S. unit

Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296) will spin out its innovation business to help accelerate its pipeline towards commercialization. The spinout will be a wholly owned subsidiary based in the U.S and have a new CEO...
BioCentury | Feb 14, 2019
Company News

India's Glenmark spinning out innovative assets into U.S. unit

Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296) will spin out its innovation business to help accelerate its pipeline towards commercialization. The spinout will be a wholly owned subsidiary based in the U.S and have a new CEO...
BioCentury | Apr 13, 2018
Targets & Mechanisms

Hello RNA

...could restore sensitivity to docetaxel in resistant prostate cancers. University of Nebraska Medical Center 5897 Prostaglandin E synthase-3 (PTGES3)...
BioCentury | Feb 18, 2016
Product R&D

Crossing paths

Selina Koch, Staff Writer With its first foray into the brain, Catabasis Pharmaceuticals Inc. is using its linker technology to simultaneously target the inflammatory and oxidative stress pathways that drive neurodegeneration, starting with amyotrophic lateral...
BioCentury | Jan 28, 2016
Distillery Therapeutics

Therapeutics: Microsomal prostaglandin E synthase-1 (PTGES; mPGES-1); prostaglandin E2 (PGE2)

Neurology INDICATION: Pain Cell culture, human blood and guinea pig studies identified PTGES inhibitors that could help treat arthritis-related pain. In in vitro enzymatic activity assays, two compounds based on different scaffolds inhibited PTGES activity...
BioCentury | Apr 14, 2014
Clinical News

GRC 27864: Phase I start

Glenmark said it will "soon" begin a U.K. Phase I trial of oral GRC 27864. Glenmark is developing GRC 27864 under a 2012 deal with Forest Laboratories Inc. (NYSE:FRX, New York, N.Y.) to develop PTGES...
BioCentury | Jan 20, 2014
Company News

Cadila Pharmaceuticals, NovaSaid deal

NovaSaid and Cadila partnered to develop NovaSaid's therapeutic candidates for inflammation and pain, including rheumatoid arthritis (RA). The companies will collaborate on preclinical and clinical testing. Development will be conducted at Cadila's facility in Ahmedabad,...
BioCentury | Aug 12, 2013
Clinical News

LY3023703: Phase II started

Eli Lilly disclosed in its 2Q13 earnings that it began a Phase II trial to evaluate LY3023703. The product is also in Phase II testing to treat pain following wisdom teeth removal. Eli Lilly and...
BioCentury | Mar 11, 2013
Emerging Company Profile

FPRT Bio: Neutralizing neuroinflammation

FPRT Bio Inc. is developing a protein therapeutic that could halt neurodegeneration in amyotrophic lateral sclerosis and Parkinson's disease by blocking inflammatory signaling that causes neuronal cell death. FPRT's sole asset is XPro1595 , a subcutaneously...
Items per page:
1 - 10 of 15